Course Opens
03/17/2025
Credits
1
Credit Expires
03/17/2026
Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further, the available chemotherapies are associated with significant adverse effects that negatively impact quality of life for the patient. Emerging therapies with novel mechanisms of action and adverse effect profiles, such as folate receptor alpha-targeting antibody-drug conjugates (FRα ADCs), will be required for effective management of platinum-resistant ovarian cancer.
In this CE Concepts Snack, expert faculty will address critical gaps in clinician knowledge and competence by equipping learners with strategies to categorize treatment options and optimize patient-specific care plans incorporating novel therapies. Faculty will also explore approaches to mitigating disparities in ovarian cancer care, ensuring learners can implement equitable, evidence-based practices that enhance patient outcomes.
At the conclusion of this activity, learners will be able to better:
This activity is supported by an independent educational grant from Genmab US, Inc.
Medical oncologists, gynecologic oncologists, gynecologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other clinicians who care for patients with ovarian cancer
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-25-002-H01-P).
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
Care Continuum
Oncology Nursing Practice
Treatment
CBCN®
Care Continuum
Treatment
CPHON®
Care Continuum
Treatment
AOCNP®
Care Continuum
Professional Practice/Performance
Roles of the APRN
Treatment
BMTCN®
Professional Practice/Performance
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 03/17/2026. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CE Concepts, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Moore reports the following financial relationships:
Advisory Board: Aadi Bioscience; AbbVie Inc.; AstraZeneca; Caris Life Sciences; Corcept Therapeutics; Daiichi Sankyo; Duality Biologics; BioNTech SE; Eisai Inc.; Genmab; Genentech, Inc./Roche; GSK; ImmunoGen, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; Schrodinger, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Verastem; and Zentalis
Consultant: AstraZeneca; Genmab; and GSK
Research Support: GSK; Lilly; Merck & Co., Inc; and PTC Therapeutics
Other financial or material support: Associate Director, GOG Partners
Dr. Lee reports the following financial relationships:
Advisory Board: Oncusp Therapeutics and ProfoundBio, Inc./Genmab
Research Support: Research funding paid to the institution: KSQ Therapeutics, Inc./Roche; Merck & Co., Inc.; OnCusp Therapeutics; ProfoundBio, Inc./Genmab; Repare Therapeutics; and Seagen
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
SN-252-031725-88
Call us at 859-260-1717 • info@ceconcepts.com
